Sanofi And AstraZeneca Still Lead In RSV But Pfizer Has Chance To Challenge

Pandemic Affected Trial Results

 
• By Andrew McConaghie
RSV patient
Cases of RSV have rebounded after the pandemic lockdowns were lifted • Source: Alamy

More from Business

More from Scrip